Galderma Announces Departure of Its Chief Financial Officer
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that Thomas Dittrich, Chief Financial Officer, will be leaving the company to pursue another senior executive opportunity outside the organization.
Galderma launches new ALASTIN Restorative Skin Complex with Next Generation TriHex Technology®
Galderma Group AG (SWX:GALD), the pure-play dermatology category leader, announced today that ALASTIN, a leader in medical-grade peptide-based regenerative skincare, has officially launched their latest skincare innovation with the introduction of Restorative Skin Complex with Next Generation TriHex Technology® (TriHex+™). This newly enhanced formula can be used as a multi-functional, daily rejuvenating serum to support the skin’s natural collagen and elastin production that declines from aging as well as the visible loss of volume in skin impacted by factors such as facial aging or medication-driven weight loss. Restorative Skin Complex with TriHex+ joins ALASTIN’s other world class and award-winning products that are science-led and physician-endorsed.
Galderma Delivers 2024 Record Net Sales of 4.410 Billion USD, up 9.3% Year-on-Year at Constant Currency1, and Record Core EBITDA of 1.031 Billion USD, While Preparing to Accelerate Its Growth Trajectory Into 2025 and Beyond
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2024, delivering strong results for another consecutive year while making significant progress with its blockbuster platforms and future growth drivers.
Galderma Delivers Record Net Sales of 3.259 B USD in the First Nine Months of 2024, Demonstrates Significant Innovation Progress, Confirms and Narrows Its Full Year Net Sales Guidance
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2024, reporting record net sales and significant progress across its product categories and key future growth drivers.
Galderma Delivers a Strong Start to the Year With Record Net Sales of Over 1 Billion USD for the First Quarter and 12.4% Year-on-Year Growth
Galderma Group AG (SWX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2024.
